A comprehensive approach that examines the intersection of multiple biological processes is necessary to elucidate the development of stress-related disorders.
In a new study, investigators from McLean Hospital, a member of the Mass General Brigham health care system, working with colleagues at The University of Texas at Austin and Lieber Institute for Brain Development, uncovered both shared and distinct molecular changes across brain regions, genomic layers, cell types, and blood in individuals with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD).
These results, published May 24 in Science, could provide potential avenues for novel therapeutics and biomarkers.
Study Highlights
- Study combines analyses of multiple genomic platforms over multiple brain regions to probe biological processes and underlying mechanisms of stress-related disorders
- Results lay groundwork for future diagnostics and targeted treatments
“PTSD is a complex pathological condition. We had to extract information across multiple brain regions and molecular processes to capture the biological networks at play,” said first author Nikolaos P. Daskalakis, MD, PhD, director of the Neurogenomics and Translational Bioinformatics Laboratory at McLean Hospital, and an associate professor of psychiatry at Harvard Medical School.
Stress-related disorders develop over time, stemming from epigenetic modifications caused by the interplay between genetic susceptibility and traumatic stress exposure.
Previous studies have uncovered hormonal, immune, methylomic (epigenetics), and transcriptomic (RNA) factors mostly in peripheral samples contributing to these diseases, but limited access to postmortem brain tissues from diseased PTSD patients has restricted characterization of brain-based molecular changes at the appropriate scale.
“Our primary goals for this study were to interpret and integrate differential gene and protein expression, epigenetic alterations, and pathway activity across our postmortem brain cohorts in PTSD, depression, and neurotypical controls,” said senior author Kerry J. Ressler, MD, PhD, chief scientific officer, chief of the Division of Depression and Anxiety Disorders, and director of the Neurobiology of Fear Laboratory at McLean Hospital, and a professor of psychiatry at Harvard Medical School.
“We essentially combined circuit biology with powerful multi-omics tools to delve into the molecular pathology behind these disorders.”
For this, the team analyzed multi-omic data from 231 PTSD, MDD, and neurotypical control subjects, along with 114 individuals from replication cohorts for differences in three brain regions—the medial prefrontal cortex (mPFC), hippocampal dentate gyrus (DG), and central nucleus of the amygdala (CeA).
They also performed single-nucleus RNA sequencing (snRNA-seq) of 118 PFC samples to study cell-type-specific patterns and evaluated blood-based proteins in more than 50,000 UK Biobank participants to isolate key biomarkers associated with stress-related disorders. Finally, the overlap of these key brain-based disease process genes was compared with genome-wide association studies (GWAS)-based risk genes to identify PTSD and MDD risk.
PTSD and MDD individuals both shared altered gene expression and exons in the mPFC but differed in the localization of epigenetic changes. Further analysis revealed that history of childhood trauma and suicide were strong drivers of molecular variations in both disorders. The authors noted that MDD disease signals were more strongly associated with male-specific results, suggesting that sex differences may underlie disease risk.
Top disease-associated genes and pathways across regions, omics, and/or traits implicated biological processes in both neuronal and non-neuronal cells. These included molecular regulators and transcription factors, along with pathways involved in immune function, metabolism, mitochondria function, and stress hormone signaling.
“Understanding why some people develop PTSD and depression and others don’t is a major challenge,” said investigator Charles B. Nemeroff, MD, PhD, chair of the Department of Psychiatry and Behavioral Sciences at Dell Medical School of UT Austin.
“We found that the brains of people with these disorders have molecular differences, especially in the prefrontal cortex. These changes seem to affect things like our immune system, how our nerves work, and even how our stress hormones behave.”
The genetic components of the work built on a study published last month by researchers, including Ressler and Daskalakis in Nature Genetics, in which they identified 95 locations, or loci in the genome (including 80 new) associated with PTSD. Their multi-omic analyses found 43 potential causal genes for the disorder.
The researchers now could reveal only limited overlap between the top genes and those implicated in GWAS studies, underscoring the gap in current understanding between disease risk and underlying disease processes. In contrast, they discovered greater correlations between brain multi-omics and blood markers.
“Our findings support the development of brain-informed blood biomarkers for real-time profiling,” said Daskalakis.
Ressler added, “These biomarkers could help overcome current challenges in obtaining brain biopsies for advancing new treatments.”
Limitations of the study include the inherent biases in postmortem brain research, including population selection, clinical assessment, co-occurring disorders, and end-of-life state. The authors also caution that they did not fully characterize all cell subtypes and cell states, and that future studies are required to understand contrasting molecular signals across omics or brain regions.
The team plans on using this database as groundwork for future analysis of how genetic factors interact with environmental variables to create downstream disease effects.
Media Requests
Journalist or member of the media? We are available 24/7 for media requests.
